What is Celyad?
Headquartered in Mont-Saint-Guibert, Belgium, with a strategic footprint in New York, Celyad operates at the intersection of biotechnology and advanced medicine. The company is dedicated to the development of both autologous and allogeneic CAR-T therapies, utilizing a sophisticated platform designed to address high-unmet-need conditions such as acute myeloid leukemia and metastatic colorectal cancer. As a publicly traded entity on Euronext Brussels, Euronext Paris, and the Nasdaq Global Market, Celyad maintains a rigorous focus on scientific excellence and clinical validation, positioning itself as a key player in the global immuno-oncology landscape.
How much funding has Celyad raised?
Celyad has raised a total of $180.7M across 4 funding rounds:
Series B
$8.1M
Stock Offering
$100.1M
Share Placement
$40M
Share Placement
$32.5M
Series B (2009): $8.1M with participation from Grifols, Hunza Ventures SCA Hunza Ventures, and Life Sciences Research Partners
Stock Issuance/Offering (2015): $100.1M, investors not publicly disclosed
Share Placement (2021): $40M supported by Lincoln Park Capital
Share Placement (2021): $32.5M featuring Fortress Investment Group
Key Investors in Celyad
Grifols
Grifols is a global healthcare leader based in Spain, specializing in plasma-derived medicines and committed to long-term innovation in the life sciences sector.
Hunza Ventures
Hunza Ventures is a specialized venture capital firm that focuses on early-stage life sciences and information technology, providing both capital and entrepreneurial expertise.
Life Sciences Research Partners
Life Sciences Research Partners is a non-profit scientific institution dedicated to fostering biomedical and biotechnological research through strategic funding and institutional support.
What's next for Celyad?
Looking ahead, Celyad is poised to leverage its recent capital injection to accelerate its clinical trial milestones and refine its cell engineering techniques. The company's strategic roadmap emphasizes the expansion of its therapeutic portfolio, aiming to solidify its competitive advantage in the rapidly evolving CAR-T sector. By maintaining a disciplined approach to research and development, Celyad is well-positioned to navigate the complexities of the biopharmaceutical market, potentially delivering transformative treatments that could redefine standard-of-care protocols for oncology patients worldwide.
See full Celyad company page
